“So from it's somewhat academic. But I expect we will pace back steadily to low double-digit ranges and continue to advance from there.”

In context

“price. Stephen Hensley: Thank you. Next question, please. Operator: Our next question comes from Josh Raskin with Nephron Research. Josh Raskin: Thanks. Good morning. I appreciate some of the commentary you've made on 2026 and 2027 even. Do you have an updated view on your long-term EPS growth rate that, you know, was formerly cited as thirteen to sixteen percent at the enterprise level. And then I heard the target margin's obviously updated for Optum Health. But do you have updated target margins for maybe UHC in its entirety as well as the other two segments within Optum? Stephen Hensley: Yeah. Thanks, Josh, for the question. You know, as you can appreciate, as we're just coming back on stream, in the near term, our growth rates do not reflect, I think, the potential of this enterprise. So from it's somewhat academic. But I expect we will pace back steadily to low double-digit ranges and continue to advance from there. And I think importantly, the framework for our long-term growth outlook remains very much intact. From within well-run businesses, reasonable year-over-year organic growth, the compounding effect of deliberate productivity gains, the compounding effect of capital applied in the form of share buyback as we return value and capital to shareholders and the compounding effect of capital used in evolving the business model toward a more expansive view of the healthcare markets. That is less fragmented and more integrated to better serve consumers and the overall system. And the components of that should allow us to continue to grow at strong levels we've experienced in the past. And that's our outlook on it. And, Josh, just maybe a little bit on margin. Maybe Tim has a comment. He made some co”